Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Gains from Sales and Divestitures (2024)

Historic Gains from Sales and Divestitures for Zevra Therapeutics (ZVRA) over the last 1 years, with Q4 2024 value amounting to $765945.0.

  • Zevra Therapeutics' Gains from Sales and Divestitures changed N/A to $765945.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $765945.0, marking a year-over-year change of. This contributed to the annual value of $765945.0 for FY2024, which is N/A changed from last year.
  • As of Q4 2024, Zevra Therapeutics' Gains from Sales and Divestitures stood at $765945.0.
  • Over the past 5 years, Zevra Therapeutics' Gains from Sales and Divestitures peaked at $765945.0 during Q4 2024, and registered a low of $765945.0 during Q4 2024.